Choong Ang Vaccine Laboratory Co. Ltd - Asset Resilience Ratio
Choong Ang Vaccine Laboratory Co. Ltd (072020) has an Asset Resilience Ratio of 10.35% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Choong Ang Vaccine Laboratory Co. Ltd working capital to net assets to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2014–2025)
This chart shows how Choong Ang Vaccine Laboratory Co. Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Choong Ang Vaccine Laboratory Co. Ltd total assets.
Liquid Assets Composition Over Time
This chart breaks down Choong Ang Vaccine Laboratory Co. Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore 072020 long-term asset investment ratio to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩12.99 Billion | 10.35% |
| Total Liquid Assets | ₩12.99 Billion | 10.35% |
Asset Resilience Insights
- Moderate Liquidity: Choong Ang Vaccine Laboratory Co. Ltd has 10.35% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
Choong Ang Vaccine Laboratory Co. Ltd Industry Peers by Asset Resilience Ratio
Compare Choong Ang Vaccine Laboratory Co. Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI |
Drug Manufacturers - Specialty & Generic | 1.54% |
|
Yunnan Baiyao Group Co Ltd
SHE:000538 |
Drug Manufacturers - Specialty & Generic | 8.38% |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317 |
Drug Manufacturers - Specialty & Generic | 6.62% |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Harbin Gloria Pharmaceuticals
SHE:002437 |
Drug Manufacturers - Specialty & Generic | 9.04% |
|
Jiuzhitang Co Ltd
SHE:000989 |
Drug Manufacturers - Specialty & Generic | 7.86% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557 |
Drug Manufacturers - Specialty & Generic | 0.29% |
Annual Asset Resilience Ratio for Choong Ang Vaccine Laboratory Co. Ltd (2014–2025)
The table below shows the annual Asset Resilience Ratio data for Choong Ang Vaccine Laboratory Co. Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 11.21% | ₩13.77 Billion ≈ $9.33 Million |
₩122.82 Billion ≈ $83.23 Million |
-12.44pp |
| 2024-12-31 | 23.65% | ₩29.15 Billion ≈ $19.76 Million |
₩123.28 Billion ≈ $83.54 Million |
+0.72pp |
| 2023-12-31 | 22.93% | ₩27.42 Billion ≈ $18.58 Million |
₩119.59 Billion ≈ $81.05 Million |
+7.27pp |
| 2022-12-31 | 15.66% | ₩17.98 Billion ≈ $12.19 Million |
₩114.86 Billion ≈ $77.84 Million |
-3.35pp |
| 2021-12-31 | 19.00% | ₩21.47 Billion ≈ $14.55 Million |
₩112.95 Billion ≈ $76.55 Million |
-2.68pp |
| 2020-12-31 | 21.69% | ₩22.77 Billion ≈ $15.43 Million |
₩104.98 Billion ≈ $71.14 Million |
+0.22pp |
| 2019-12-31 | 21.47% | ₩20.73 Billion ≈ $14.05 Million |
₩96.57 Billion ≈ $65.44 Million |
-3.62pp |
| 2018-12-31 | 25.09% | ₩24.27 Billion ≈ $16.45 Million |
₩96.74 Billion ≈ $65.56 Million |
+6.69pp |
| 2017-12-31 | 18.40% | ₩15.02 Billion ≈ $10.18 Million |
₩81.62 Billion ≈ $55.32 Million |
-8.91pp |
| 2016-12-31 | 27.31% | ₩20.09 Billion ≈ $13.61 Million |
₩73.54 Billion ≈ $49.84 Million |
+19.11pp |
| 2015-12-31 | 8.21% | ₩5.10 Billion ≈ $3.45 Million |
₩62.10 Billion ≈ $42.09 Million |
+2.19pp |
| 2014-12-31 | 6.02% | ₩3.65 Billion ≈ $2.47 Million |
₩60.60 Billion ≈ $41.07 Million |
-- |
About Choong Ang Vaccine Laboratory Co. Ltd
Choong Ang Vaccine Laboratory Co., Ltd. engages in the research, development, manufacturing, and sale of animal vaccines in South Korea, Asia, Africa, and the United States. It offers swine, poultry, cattle, canine, feline, wild boar, and raccoon vaccines under the SuiShot, PoulShot, BoviShot, CaniShot, and FeliShot brands. The company was founded in 1968 and is headquartered in Daejeon, South Ko… Read more